GT200400135A - Sistemas semi-solidos que contienen derivados de azetidina - Google Patents

Sistemas semi-solidos que contienen derivados de azetidina

Info

Publication number
GT200400135A
GT200400135A GT200400135A GT200400135A GT200400135A GT 200400135 A GT200400135 A GT 200400135A GT 200400135 A GT200400135 A GT 200400135A GT 200400135 A GT200400135 A GT 200400135A GT 200400135 A GT200400135 A GT 200400135A
Authority
GT
Guatemala
Prior art keywords
azetidine
systems containing
semi
containing derivatives
solid systems
Prior art date
Application number
GT200400135A
Other languages
English (en)
Inventor
Maria Teresa Peracchia
Sophie Cote
Valerie Bobineau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200400135A publication Critical patent/GT200400135A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÒN SE REFIERE A SISTEMAS SEMISÒLIDOS QUE CONTIENEN DERIVADOS DE AZETIDINA. ESTOS COMPUESTOS SON PARTICULARMENTE VENTAJOSOS POR SU ALTA AFINIDAD POR RECEPTORES DE CANNABINOIDES Y EN PARTICULAR POR RECEPTORES DE TIPO CB1 POR LO QUE SON DE UTILIDAD PARA UNA ACTIVA NEUROTRANSMISIÒN EN EL CEREBRO.
GT200400135A 2003-07-18 2004-07-16 Sistemas semi-solidos que contienen derivados de azetidina GT200400135A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291796A EP1498122A1 (en) 2003-07-18 2003-07-18 Semi-solid systems containing azetidine derivatives

Publications (1)

Publication Number Publication Date
GT200400135A true GT200400135A (es) 2005-08-25

Family

ID=33462259

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400135A GT200400135A (es) 2003-07-18 2004-07-16 Sistemas semi-solidos que contienen derivados de azetidina

Country Status (30)

Country Link
US (2) US20050026898A1 (es)
EP (2) EP1498122A1 (es)
JP (1) JP2009513560A (es)
KR (1) KR20060040691A (es)
CN (1) CN1822831A (es)
AR (1) AR045997A1 (es)
AU (1) AU2004262498B2 (es)
BR (1) BRPI0412737A (es)
CA (1) CA2532669A1 (es)
CR (1) CR8179A (es)
EC (1) ECSP066292A (es)
GT (1) GT200400135A (es)
HR (1) HRP20060022A2 (es)
IL (1) IL173111A0 (es)
MA (1) MA27922A1 (es)
MX (1) MXPA06000483A (es)
MY (1) MY142077A (es)
NO (1) NO20060509L (es)
OA (1) OA13191A (es)
PA (1) PA8606701A1 (es)
PE (1) PE20050287A1 (es)
RS (1) RS20060016A (es)
RU (1) RU2343915C2 (es)
SG (1) SG144141A1 (es)
TN (1) TNSN06013A1 (es)
TW (1) TW200522945A (es)
UA (1) UA80633C2 (es)
UY (1) UY28421A1 (es)
WO (1) WO2005013973A1 (es)
ZA (1) ZA200600490B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817012A2 (en) * 2004-11-24 2007-08-15 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
FR2923719B1 (fr) * 2007-11-15 2009-11-20 Sanofi Aventis Compositions pharmaceutiques a base de derives d'azetidine
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
EP2637655B1 (en) * 2010-11-08 2019-01-09 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of taxoids
CN105848643A (zh) * 2013-12-23 2016-08-10 强生消费者公司 消旋卡多曲组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
WO2000003753A2 (en) * 1998-07-14 2000-01-27 Em Industries, Inc. Microdisperse drug delivery systems
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives

Also Published As

Publication number Publication date
TNSN06013A1 (en) 2007-10-03
AR045997A1 (es) 2005-11-23
UA80633C2 (en) 2007-10-10
AU2004262498A1 (en) 2005-02-17
SG144141A1 (en) 2008-07-29
IL173111A0 (en) 2006-06-11
ECSP066292A (es) 2006-10-25
CN1822831A (zh) 2006-08-23
UY28421A1 (es) 2005-02-28
RU2343915C2 (ru) 2009-01-20
RU2006105011A (ru) 2006-06-10
EP1648442A1 (en) 2006-04-26
BRPI0412737A (pt) 2006-09-26
HRP20060022A2 (en) 2006-02-28
AU2004262498A2 (en) 2005-02-17
RS20060016A (en) 2008-06-05
US20050026898A1 (en) 2005-02-03
JP2009513560A (ja) 2009-04-02
OA13191A (en) 2006-12-13
WO2005013973A1 (en) 2005-02-17
MA27922A1 (fr) 2006-06-01
CR8179A (es) 2006-09-22
NO20060509L (no) 2006-01-31
AU2004262498B2 (en) 2009-01-22
US20080293686A1 (en) 2008-11-27
TW200522945A (en) 2005-07-16
MXPA06000483A (es) 2006-04-05
ZA200600490B (en) 2007-05-30
KR20060040691A (ko) 2006-05-10
CA2532669A1 (en) 2005-02-17
PE20050287A1 (es) 2005-06-13
MY142077A (en) 2010-08-30
EP1498122A1 (en) 2005-01-19
PA8606701A1 (es) 2005-02-04

Similar Documents

Publication Publication Date Title
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
NI200600094A (es) Compuesto heterociclicos fusionados
CR8387A (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos
GT200400032A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
PE20081506A1 (es) Formulaciones de ansamicina
CR20140422A (es) Composiciones de enzima digestiva estable
HN2003000416A (es) Derivados de pirrolopirimidina
GT200200148A (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gaba a
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
ECSP034600A (es) Compuestos de lactama
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
UY28602A1 (es) Compuestos quimicos
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
BRPI0414599A (pt) pirrol-indóis substituìdos
PA8667201A1 (es) Nuevos compuestos farmaceuticos
ECSP045255A (es) Cumarinas utiles como biomarcadores
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
GT200300072AA (es) Aminoacidos con afinidad por la proteina alfa2delta (solicitud fraccionaria
ECSP066822A (es) Macrólidos y métodos para producir los mismos
JO2578B1 (en) Compounds Theophene benzimidazole